Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion type Assertion NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_head.
- NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_provenance.
- NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion evidence source_evidence_literature NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_provenance.
- NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion SIO_000772 22200442 NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_provenance.
- NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion wasDerivedFrom befree-20150227 NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_provenance.
- NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_assertion wasGeneratedBy ECO_0000203 NP589108.RAv2Sqgr3_i4tfn6bd4FsQV5X9NUXCM89plNp1DWvM7uA130_provenance.